Thrombin-Activatable Fibrinolysis Inhibitor in Breast Cancer Patients

Creative Commons License

Kaftan O., KASAPOĞLU B., Koroglu M., KOŞAR A., Yalcin S.

MEDICAL PRINCIPLES AND PRACTICE, cilt.20, sa.4, ss.332-335, 2011 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 20 Sayı: 4
  • Basım Tarihi: 2011
  • Doi Numarası: 10.1159/000324547
  • Dergi Adı: MEDICAL PRINCIPLES AND PRACTICE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.332-335
  • Anahtar Kelimeler: Thrombin-activatable fibrinolysis inhibitor, Breast cancer, BLOOD-COAGULATION, RISK, TESTS, TAFI
  • Lokman Hekim Üniversitesi Adresli: Hayır

Özet

Objective: To evaluate the levels of thrombin-activatable fibrinolysis inhibitor (TAFI) activity and also its relationship with other homeostasis markers in breast cancer patients. Subjects and Methods: Forty-two female patients with breast cancer and 24 healthy women (controls) were enrolled in the study and fasting blood samples of all cases were drawn from a large antecubital vein for assay of TAFI and other homeostasis tests. Results: The TAFI levels were 79.5 +/- 15.5 and 39.3 +/- 12.1 in patients and controls, respectively, and the difference was statistically significant (p < 0.001). In the patient group, the serum fibrinogen level was 504.9 +/- 224.8, while in the control group it was 393.9 +/- 100.5, and the difference was also statistically significant (p < 0.001). Conclusion: The data showed that increased levels of TAFI are a contributing factor of thrombotic disorders in breast cancer patients. Copyright (C) 2011 S. Karger AG, Basel